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Abstract Objective Obesity is associated with an increased risk for breast cancer. Recent
studies have shown that aromatase inhibitors may be less effective in women with a
high body mass index (BMI). The aim of this study was to establish the relationship
between the BMI and plasma estrone and estradiol levels in postmenopausal women
with hormone receptor-positive breast cancer using anastrozole.
Methods In this cohort study, the patients were divided into three groups according
to BMI (normal weight, overweight and obese) to compare and correlate plasma
hormone levels before starting anastrozole hormone therapy and three months after
treatment. Plasma hormone levels were compared for age and use of chemotherapy.
Results A statistically significant reduction in estrone and estradiol levels was
observed between baseline and three months after starting the anastrozole treatment
(p < 0.05). There was no statistically significant difference in plasma estrone and
estradiol levels among the BMI groups (p > 0.05), but a significant reduction in plasma
estrone levels was observed after three-months’ treatment relative to baseline in all
groups, as well as a reduction in estradiol in the obese group (p < 0.05). The use of
chemotherapy and age > 65 years had no influence on plasma steroid levels.
Conclusion Changes in estrone and estradiol levels in the studied groups were not
associated with BMI, chemotherapy or age.
Resumo Objetivo A obesidade está associada com risco aumentado de câncer de mama.
Estudos recentes têm mostrado que os inibidores de aromatase podem ser menos
eficazes emmulheres com alto índice demassa corporal (IMC). O objetivo deste estudo
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Breast cancer is the neoplasm that causes the highest num-
ber of deaths among Brazilian women. The estimates for the
year 2014 in Brazil were around 57,120 new cases, according
to data from the Brazilian National Cancer Institute.1 The
disease is also considered a public health problem in the
United States, where the estimate for 2012 was of 229,060
new cases and 39,920 deaths.2
Older age is the biggest risk factor for breast cancer, and
other risk factors are also well established, including early
menarche, nulliparity, prolonged use of oral contraceptives,
late menopause, menopausal hormone therapy for over five
years, family history of breast cancer, and high density of
breast tissue.1
Serum estrogen and androgen levels in postmenopausal
women also affect the risk of breast cancer. An elevated
plasma estrone level is strongly associated with the risk of
developing the disease, and in women with estradiol or
testosterone levels 20–25% above the mean values, the inci-
dence of breast cancer is 2 to 3 times higher.3
Besides the above-mentioned factors, Cintra et al4 and
Friedenreich5 reported that obesity is correlated with a 30–
50% higher relative risk of breast cancer in menopausal
women, and that this population has a greater risk of death
and recurrence.6,7 According to Colditz et al8 and Suzuki
et al9, there is a positive association between high bodymass
index (BMI) and breast cancer risk in post-menopausal
patients with hormone receptor-positive tumors.
Approximately 78% of breast tumors are hormone depen-
dent. Therefore, stopping the action of estrogen in the breast
is a known therapeutic approach for preventing recurrence,
and it can be achieved by blocking the hormone’s action on
the estrogen receptors or stopping its synthesis.10
During a woman’s period of menstrual activity, estrogens
are synthesizedmainly by the ovaries. In the postmenopaus-
al phase, the suprarenal cortex and the ovaries produce
androgens, which are then converted into estrogens by the
aromatase enzyme, an enzyme complex that is part of the
cytochrome P-450 family and is present mainly in the adi-
pose tissue, striated muscles, the liver, and breast tumors.11
According to Diorio et al10, an elevated BMI is associated
with higher estrogen levels in postmenopausal women due
to the fact that the adipose tissue is the main site for the
synthesis of these steroids. These increased estrogen levels
may play a role in the development of breast tumors.
According to Diorio et al10, an elevated BMI is associated
with higher estrogen levels in postmenopausal women due
to the fact that the adipose tissue is the main site for the
synthesis of these steroids. These increased estrogen levels
may play a role in the development of breast tumors.
Aromatase inhibitors belong to a group of drugs widely
used for breast cancer hormone therapy, whose aim is to
decrease estrogen levels and deactivate the aromatase com-
plex, in order to stop the conversion of androstenedione into
estrone, and of testosterone into estradiol. Anastrozole is the
best-known example from this group of drugs.12
Anastrozole’s action is exerted through a competitive link
with the aromatase enzyme, and it decreases estrogen
biosynthesis in all tissues. Inmenopausalwomenwith breast
cancer, anastrozole at 1mg/day inhibits aromatization by
96.7%, and suppresses plasma estrone and estradiol concen-
trations by  84–94%.13
According to Sestak et al14, aromatase inhibitors seem
to be more effective in leaner menopausal women. There
are data demonstrating an increased risk of breast cancer
recurrence, and of death after recurrence, among women
who have elevated BMIs undergoing hormone therapy
mulheres no período pós-menopausa com câncer de mama receptor hormonal
positivo, em tratamento com anastrozol.
Métodos Este estudo de coorte acompanhou três grupos de pacientes de acordo com
o seu IMC (peso normal, sobrepeso e obesidade), a fim de comparar e correlacionar as
dosagens dos hormônios estrona e estradiol antes e após três meses do uso do
anastrozol. Os níveis plasmáticos dos hormônios foram também relacionados à idade
do paciente e ao uso da quimioterapia.
Resultados Redução estatisticamente significativa de estrona e estradiol foi obser-
vada entre os níveis basais e três meses após o início do tratamento com anastrozol
(p < 0,05). Não houve diferença estatisticamente significativa entre os níveis plasmá-
ticos de estrona e estradiol em relação ao IMC (p > 0,05), mas houve redução
significativa entre os níveis plasmáticos basais de estrona após o tratamento em todos
os grupos, e redução de estradiol no grupo de pacientes obesas (p < 0,05). A condução
da quimioterapia e da idade acima de 65 anos não interfere com os níveis plasmáticos
de esteroides.
Conclusão Os níveis plasmáticos de estrona e estradiol nos grupos estudados não
foram alterados em termos de IMC, quimioterapia e idade.
Palavras-chave
► neoplasias de mama
► estrona
► estradiol
► índice de massa
corporal
► anastrozol
Rev Bras Ginecol Obstet Vol. 39 No. 1/2017
Estrone and Estradiol Levels in Breast Cancer Patients are not related to BMI Coscia et al. 15
with anastrozole compared with patients treated with
tamoxifen.15 A possible explanation for this relationship
is that women with elevated BMIs have higher estrogen
levels due to the incomplete inhibition of the peripheral
aromatization by anastrozole.14
Studies such as that by Goodwin and Pritchard15 examine
whether patients with elevated BMIs need higher doses of
aromatase inhibitors in order to reach therapeutic levels of
estrogen suppression. The present study sought to evaluate
estrone and estradiol suppression by anastrozole in post-
menopausal patients with hormone receptor-positive breast





Patients diagnosed with breast cancer, in the postmenopausal
phase, andoncologically indicated for adjuvant hormone therapy
with anastrozolewere selected to participate in the study during
the period of hormone therapy prescription. All participants had
natural menopause and had not been submitted to hormone
treatment during this phase. The patients were drawn from four
centers specialized in oncology and breast cancer treatment
located in the city of Sorocaba, in the state of São Paulo, Brazil.
Eligibility Criteria
Patients diagnosed with: hormone receptor expression for
estrogen and progesterone in breast cancer; post-meno-
pause status characterized by amenorrhea for over a year
before the beginning of the oncological treatment; and
indicated for anastrozole hormone therapy were included.
Patients were excluded for the following: previous treat-
ment with tamoxifen; contraindication for the use of anas-
trozole; previous hysterectomy or oophorectomy; the use of
menopausal hormone therapy during the study period; cor-
ticosteroid treatment during the study period;mental deficits
that could affect the understanding of study; individuals that
interrupted treatment due to personal reasons or oncological
indication; disease recurrence during study period; and those
unable to use anastrozole during study period.
Clinical Protocol
The initial care of each patient was conducted at the time of the
beginning of the anastrozole treatment. All participants had
medical prescriptions and access to the medication, which was
provided by pharmacies within the city’s oncological center.
Appointments were scheduled in the morning period between
7amand8am, so that patients could followan eight-hour fasting.
The clinical protocol for the first appointment included: an
interview and an analysis of the medical charts in order to
obtain the clinical and epidemiological data; BMImeasurement
(kg/m2) according to the World Health Organization (WHO);
blood collection; and orientation on the use of anastrozole
regarding posology (single oral dose of 1mg/day), and on the
importance of adhering to the treatment and recording the
possible adverse effects related to the medication. The patients
were asked to keep the empty medication boxes and blisters so
that they could be checked on the second appointment.
The second appointment was conducted 90  7 days after
the first appointment. The patients were resubmitted to an
interview and an analysis of the medical charts in order to
complement the clinical information, reevaluate the anthro-
pometric data and collect a new blood sample for the
determination of plasma steroid levels.
In order to evaluate the relationship between the BMI and
thesuppressionofestroneandestradiol byanastrozole, patients
were divided into three groups: 1) normal weight patients
(BMI < 25.00 kg/m2); 2) overweight patients (BMI of 25.00–
29.99 kg/m2); and obese patients (BMI > 30.00 kg/m2). The
influence of age (< 65 and  65 years old) and chemotherapy
use (yes/no) on the plasma levels of these steroids was also
investigated.
The adherence to the anastrozole treatment was checked
by verifying the records from the high-cost medicine phar-
macy where the drugs were dispensed. Adherence was also
checked by telephone contact with the patient 60 days after
the start of treatment, and confirmation was made during
the second appointment by checking the empty blisters from
the boxes of anastrozole used.
Blood Sample Collection
Blood samples (5 ml for each hormone) were centrifuged at
2,200 g for 10 minutes at a temperature of 18°C, and the
serum frozen at -20°C. Plasma estrone levels (pg/mL) were
measured by radioimmunoassay and estradiol (pg/mL) by
the competitive electrochemiluminescence-based immuno-
assay method. Values were considered within the normal
range for menopause patients when the following were
observed: estrone 103 pg/mL and estradiol  55 pg/mL.
The lower limits of detection for the methodologies em-
ployed were 10 pg/mL and 5 pg/mL respectively.
Statistical Analysis
Non-parametric tests, including the Kruskal-Wallis, Mann-
Whitney, Wilcoxon, Chi-square (χ2), and the parametric
Student’s t-test were used. Pearson’s correlation coefficient
was employed to analyze the correlation between variables.
The statistical software used was Bioestat 5.0 (Instituto
Mamirauá, Tefé, Brazil), with a significance level of 5%.
Ethical Aspects
This study was approved by the Research Ethics Committee
of Universidade de Sorocaba (protocol number 021/11). After
having understood the study, the patients formalized their
participation by signing the Free Informed Consent Form.
Results
The 38 eligible patients completed the study. The mean age
was 64.94  9.40 years, and 11 patients were of normal
weight, while 9 were overweight and 18 were obese. No
patients had their BMIs reclassified on the reevaluation of
the anthropometric indexes (►Table 1).
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Among the possible adverse effects related to anastrozole,
31.6% (n = 12) reported somediscomfort; 13.2% (n ¼ 5),muscle
pains; 10.5% (n ¼ 4), joint pains; and 7.9% (n ¼ 3) reported hot
flashes. All patients confirmed taking anastrozole daily; they
delivered the empty blisters at the second appointment, and
obtained the medicine during the period of use, which was
confirmed by checking the records at the high-cost drug
pharmacies.
A statistically significant reduction was found between
measurements at baseline and after threemonths of treatment
for both hormones (Student’s t-test, p ¼ 0.0001) (►Table 2).
The reductions averaged 48.8% for estrone and 39.9% for
estradiol.
►Fig. 1 shows plasma estrone and estradiol levels at
baseline and three months after starting treatment with
anastrozole according to BMI, age and chemotherapy use. No
difference was observed among the groups (Kruskal-Wallis
test, p  0.05) for any of the hormones studied in relation to
the BMI. There was a reduction (Wilcoxon test, p < 0.005) in
plasma estrone concentration after treatment with
Table 1 Clinical variables of breast cancer patients treated with anastrozole








23.8  0.99 27.57  1.03 34.0  3.09 29.51  5.01
Age (years)
48–64 4 4 10 18 (47.40%)
65–85 7 5 8 20 (52.60%)
Mean  SD 66.5  10.93 67.14  12.40 63.0  6.65 64.94  9.40
TM (years)
1–10 4 3 6 13 (34.10%)
> 10 7 6 12 25 (65.90%)
AM (years old)
41–50 5 4 11 20 (52.60%)
51–55 6 5 7 18 (47.40%)
Stage
I 4 2 6 12 (31.60%)
II A 2 4 5 11 (28.90%)
II B 4 3 4 11 (28.90%)
III A 1 0 2 3 (7.90%)
III C 0 0 1 1 (2.70%)
Chemotherapy
No 4 3 6 13 (34.20%)
Yes 7 6 12 25 (65.80%)
Total 11 9 18 38 (100%)
Abbreviations: AM, age at menopause; BMI, body mass index; TM, time at menopause; SD, standard deviation.
Table 2 Plasma estrone and estradiol levels (pg/mL) of menopausal women with breast cancer, before and after treatment with
anastrozole
Measurements Estrone Estradiol
Baseline (pg/mL) Post-treatment (pg/mL) Baseline (pg/mL) Post-treatment (pg/mL)
Mean  SD 26.63  5.82 13.63  4.51 10.08  7.70# 6.05  2.81#
Median 22 12 7 5
Minimum and maximum 10–79 10–25 5–41 5–16
1st and 3rd quartiles 15–28 10–15 5–13 5–5
Abbreviation: SD, standard deviation.
Note: #Statistically significant difference (Student’s t-test, p ¼ 0.0001) between measurements at baseline and post-treatment.
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anastrozole in the three groups evaluated, and a reduction in
plasma estradiol levels only for the obese group (Wilcoxon
test, p ¼ 0.0009). The correlation between BMI values and
plasma hormone concentrations after treatment with anas-
trozole was weak and non-significant (p  0.05).
No difference was found for the estradiol and estrone
groups (Mann-Whitney test, p  0.05) in relation to age.
However, a significant reduction in plasma estrone levels
(Wilcoxon test, p < 0.001) was found for both groups, where-
as a reduction in plasma estradiol levels was detected only for
the group of patients aged > 65 years (Wilcoxon test,
p ¼ 0.007). The correlation between age andplasmahormone
concentrations after the anastrozole treatment was weak and
non-significant (p  0.05).
There was no statistically significant difference among
hormone levels in the group of patients submitted to che-
motherapy treatment (Mann-Whitney test, p  0.05). A
significant reduction in plasma hormone concentrations
was observed for both groups after the anastrozole treat-
ment (Wilcoxon test, p < 0.05).
Discussion
The use of anastrozole led to a statistically significant reduc-
tion in plasma estrone and estradiol levels. However, no
Fig. 1 Plasma estrone and estradiol concentrations – median, first and third quartiles, maximum and minimum (pg/mL) values before and three
months after treatment with anastrozole, according to  body mass index (#), age (##) and chemotherapy use (###). A statistically significant
difference was observed in the intergroup comparison (Kruskal-Wallis test, p < 0.05) in the normal weight and overweight groups for plasma
estrone values at baseline. #No difference was found on the intergroup comparison (Kruskal-Wallis test, p0.05) for hormone concentrations. A
statistically significant difference was observed in the intergroup comparison (Wilcoxon test, p < 0.05) for estrone, and in the obese group, for
estradiol. ##No statistically significant difference was found on the intergroup comparison (Mann-Whitney test, p 0.05). A statistically
significant difference was found on the intergroup comparison (Wilcoxon test, p < 0.001) for estrone, and in the 65–89 year-old group, for
estradiol. ###No statistically significant difference was found on the intergroup comparison (Mann-Whitney test, p 0.05). A statistically
significant difference was found on the intergroup comparison (Wilcoxon test, p < 0.05).
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significant changes in steroid concentrations were associat-
ed with BMI group. This result contradicts the hypothesis of
the study that there would be a smaller reduction in these
hormone levels among obese patients. No influence of age or
use of chemotherapy (or otherwise) on the plasma levels of
these steroids was observed.
The group of patients included in this study comprised
predominantly older women, an expected characteristic due
to the fact that age is a risk factor for breast cancer. The
association between an elevated BMI and breast cancer risk
applies mainly to postmenopausal women,2,6,7 where obese
women have a 2.5 times greater chance of developing breast
cancer than those with a normal BMI.16
Approximately 78% of breast neoplasms are hormone
dependent in postmenopausal women, characterized by
the expression of estrogen and progesterone receptors.10
All patients involved in this study tested positive on immu-
nohistochemistry exams for the expression of receptors, a
fundamental criteria for the indication of hormone therapy,
which is considered a safe and effective treatment for breast
cancer.17
The decision to use anastrozole as the hormone therapy
for the patients involved in the research was based on the
characteristics of the population, which was composed of
women in the postmenopausal phase with breast cancer.
During this phase, treatment with aromatase inhibitors is
associated with higher disease-free survival rates than ther-
apy with tamoxifen.18,19
In menopausal women with breast cancer, anastrozole
at a dose of 1 mg/day inhibits aromatization by  97% and
suppresses plasma estrone and estradiol concentrations by
 84% and 94% respectively.13 The time required for
anastrozole to promote estrogen suppression is two to
four days.20,21 After approximately 7 days of administra-
tion, anastrozole reaches 90 to 95% of its plasma concen-
trations. In the present study, the patients were
reevaluated three months after the beginning of the treat-
ment, which is in accordance with the studies of Dixon et
al,22 Smith et al,23 and Folkerd et al.6
This time period allowed the collection of other informa-
tion regarding the adverse effects possibly attributed to
anastrozole, as well as information on the adherence to the
treatment and on the occurrence of oncological events that
patients with neoplasms are exposed to, such as treatment
complications and the possibility of the loco-regional or
distal recurrence of the disease.
Despite the benefits of hormone therapy with aromatase
inhibitors, recent reports suggest decreased efficacy, in-
creased rates of recurrence, and of death after recurrence,
with the use of anastrozole in obese postmenopausal breast
cancer patients compared with women of normal weight
undergoing treatment with anastrozole and with obese
women treated with tamoxifen.6,14,15
Folkerd et al6 confirmed a positive relationship between
estrogen levels and BMI during treatment with anastrozole;
that is, a higher BMI was associated with higher plasma
steroid concentrations. This result may help explain the
lower benefit observed when treating obese women with
anastrozole, where breast cancer is associated, among other
factors, with circulating estrogen levels.23–25
Diorio et al10 reported results similar to those of the
present study. The authors compared estradiol levels be-
tween lean and obese women treated with aromatase in-
hibitors (letrozole, exemestane or anastrozole) and found
that, although postmenopausal obese women had higher
levels of the hormone, the aromatase inhibitor therapy
appeared to be equally effective in decreasing the levels of
this steroid, irrespective of the BMI. More recently, Lønning
et al26 also found no correlation between estrogen levels and
BMI in breast cancer patients treated with letrozole or
anastrozole.
Thus, the impact of obesity on the risk of breast cancer
recurrence27 may not be due to the complete inhibition of
the peripheral conversion of androgenswithout estrogens by
aromatase in patients treatedwith anastrozole. To date, scant
studies analyzing female sex hormones according to BMI, as
investigated in the present study, have been conducted.
Body mass index is the most used anthropometric
parameter in scientific studies for characterizing the over-
weightness or obesity of an individual.14–28 Although the
BMI is an index based on height and weight that precludes
specific evaluation of lean mass and fat mass, major muscle
gain in a group of menopausal women is improbable.
Therefore, an increased BMI can be attributed to increased
body fat.29
Body fat percentage is also an anthropometric index
predicting risk. However, this evaluation in large-scale stud-
ies is subject to technical and inter-observational variations,
because it is not as easily calculated as height and weight,
which explains why most published studies use BMI calcu-
lation as a parameter to associate obesity and cancer.21,30,31
The results of the present study showed the adherence of
the group to the prescribed treatment. According to Murphy
et al32, in order to be considered adherent to treatment,
patients must exhibit evidence of the use of medication
above 80% for a given period of time.
Danilak and Chambers33 reported 78% adherence to hor-
mone therapy for breast cancer, which was retrospectively
confirmed by records held by the registered pharmacies
where the drugs were dispensed. This methodology was
also used in the present study, together with individual
confirmation of medication use by patients and the checking
of the empty anastrozole blisters. This adherence was of
100%, which is justified by the short observation period
(three), unlike the cited studies, which had a longer evalua-
tion period, of at least two years.
The adverse effects likely attributable to the use of anas-
trozole in this study were similar to those found in the
literature,18,21 in which the most frequent complaints
were of muscle pains, hot flashes, and joint pains, mirroring
those described by the Food and Drug Administration (FDA).
It was not possible to quantify plasma steroid levels below
10 pg/mL for estrone, and below 5 pg/mL for estradiol. The
ability to determine plasma steroid levels below this limit
might have resulted in a greater percentage reduction in
these hormones.
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In the literature, there are few studies evaluating the
relationship between BMI and the decreased efficacy of
aromatase inhibitors, and the available results remain con-
flicting. The results of the present study showed that changes
in plasma estrone and estradiol levels in the group studied
were not associated with BMI, chemotherapy or age.
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